CNS Pharmaceuticals, Inc.(CNSP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CNSP Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for CNS Pharmaceuticals, Inc. (CNSP), a Healthcare sector company. CNSP is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), CNS Pharmaceuticals, Inc. reports net income of $-2.6M, free cash flow of $-3.5M. Top institutional holders of CNSP by reported 13-F value include Stonepine Capital Management, Ikarian Capital, ADAR1 Capital Management, based on the most recent SEC filings. CNSP trades on the Nasdaq exchange and files with the SEC under CIK 1729427. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CNSP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CNS Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-2.6M
Free Cash Flow
Q2 2026
$-3.5M
ROIC
Q2 2026
-59.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-6.7% YoYOperating Income
-7.3% YoYEPS (Diluted)
+92.3% YoYTotal Assets
-0.9% YoYTotal Debt
Op. Cash Flow
+19.3% YoYFree Cash Flow
+19.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-15.9M -6.7% | $-14.9M +21.2% | $-18.9M -23.4% | $-15.3M -5.4% | $-14.5M -53.3% | $-9.5M |
| Operating Income | $-16.0M -7.3% | $-14.9M +21.0% | $-18.9M -23.6% | $-15.3M -5.4% | $-14.5M -53.2% | $-9.5M |
| EPS (Diluted) | $-35.75 +92.3% | $-466.89 +96.3% | $-12509.11 -111389.4% | $-11.22 +32.0% | $-16.50 | — |
| Total Assets | $8.6M -0.9% | $8.7M +411.6% | $1.7M -87.0% | $13.1M +49.1% | $8.8M -44.8% | $15.9M |
| Total Debt | — | — | — | $449.9K +5.6% | $426.0K -11.7% | $482.4K |
| Operating Cash Flow | $-13.8M +19.3% | $-17.1M -21.0% | $-14.1M -33.9% | $-10.6M +22.0% | $-13.5M -85.0% | $-7.3M |
| Free Cash Flow | $-13.8M +19.2% | $-17.1M -21.0% | $-14.1M -33.9% | $-10.6M +22.0% | $-13.5M -84.6% | $-7.3M |
Get alerted when CNSP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for CNS Pharmaceuticals, Inc. including:
Top Institutional Holders of CNSP
Stonepine Capital Management, LLC
$6.4M1,345,921 shIkarian Capital, LLC
$649.3K135,830 shADAR1 Capital Management, LLC
$334.6K70,000 shBOOTHBAY FUND MANAGEMENT, LLC
$64.6K13,524 shVANGUARD FIDUCIARY TRUST CO
$48.9K10,226 shVANGUARD CAPITAL MANAGEMENT LLC
$33.4K6,993 shUBS Group AG
$7.0K1,461 shTower Research Capital LLC (TRC)
$3.8K799 shBARCLAYS PLC
$91.0019 shBARRETT & COMPANY, INC.
$38.008 sh
| Fund | Value | Shares |
|---|---|---|
| Stonepine Capital Management, LLC | $6.4M | 1,345,921 |
| Ikarian Capital, LLC | $649.3K | 135,830 |
| ADAR1 Capital Management, LLC | $334.6K | 70,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | $64.6K | 13,524 |
| VANGUARD FIDUCIARY TRUST CO | $48.9K | 10,226 |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.4K | 6,993 |
| UBS Group AG | $7.0K | 1,461 |
| Tower Research Capital LLC (TRC) | $3.8K | 799 |
| BARCLAYS PLC | $91.00 | 19 |
| BARRETT & COMPANY, INC. | $38.00 | 8 |
More Healthcare Companies
View all Healthcare →Put CNSP on your watchlist
Track score changes the day CNS Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CNSP a good stock to buy?
13F Pro's AI-powered analysis of CNS Pharmaceuticals, Inc. (CNSP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CNSP are available on the CNSP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CNSP is classified as a small company.
Which hedge funds own CNSP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CNSP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of CNS Pharmaceuticals, Inc.'s investment landscape.